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ABSTRACT
Parupudi, S Ph.D., Purdue University, August 2018. Electrolytic Microsystems for
Biomedical Applications.
Major Professors: Allen L. Garner and Vijay Raghunathan.
With an American dying each minute due to cancer and with a global burden of
over $170 billion by 2020, there is a critical need for alternate solutions, especially
for deep-seated, inoperable tumors in the liver and brain. Systemic chemotherapy
has side eﬀects and radiation is expensive. Challenges of current technologies for
treating the liver include poor performance near vascular structures and the inability
to treat multiple nodular tumors. Brain tumor treatment suﬀers from inadequate
intra-cerebral drug concentration and uncontrollable drug delivery. These diﬃculties
motivate the development of low-cost solutions that have fractionated application and
are localized, monitored, and compatible with intra-operative imaging. This research
presents two alternative systems based on electrolytic mechanisms: an ultrasoundpowered micro-ablator for electrochemical treatment of deep-seated liver tumors and
an implantable electrophoretic ﬂushable-electrode system for controllable drug delivery to brain tumors. The micro-ablator leverages pH change, below six and above
nine for tumor tissue destruction. Using ultrasound to energize the ablator provides advantages of deep penetration, omni-directionality, device miniaturization and
possible wireless telemetry for data communication, which are all attractive for implementation in a clinical setting. The use of direct current enables delivery of charged
therapeutic substances through electrophoresis to increase their intra-tumoral concentration and penetration. The facile fabrication of novel ﬂuidic-ﬂushable channel
electrodes enables their conformability with soft tissue. Together, these two technolo-

xiv
gies enable the low-cost development of customized and localized treatment protocols
for practical applicability with a potential to reduce tumor burden.

1

1. INTRODUCTION
Cancer is a global public health issue and a quarter of the deaths each year are
accounted to cancer in the United States alone [1]. According to the American Cancer
Society, an estimated 1.68 million new cancer cases will be diagnosed in 2018 and at
least a half million deaths will occur in the US alone. Although early diagnosis and
treatment are increasing the survival rates from cancer, many solid tumors are still
fatal because they are deep-seated (e.g. liver and pancreatic tumors) and treatmentresistant (e.g. brain tumors) [2]. Of the 1.68 million, nearly 40,710 or 2.4% new
cases of liver cancer will be diagnosed in 2017 with approximately three-fourths being
hepatocellular-carcinoma (HCC). Although it is possible to treat early stage liver
cancer by surgically removing part of the liver or partial hepatectomy, the percentage
of patients who are eligible for surgical removal of tumors is low due to problems
such as inadequate remnant of healthy liver, presence of multi-nodular tumors or
due to patient declining resection [3] [4]. However, hepatic resection accounts to
only 5 to 15% of patients with a 5-year survival rate at only 20% to 40% [5] [6]
and many liver tumors are non-resectable, the reason being risk of loss of a large
quantity of healthy tissue. Large incisions, morbidity due to surgery, mortality and
unfavorable anatomical conditions [?] [6] are several other disadvantages. Despite
medical advancements in surgical techniques in the past 20 years, there has always
been the issue of unclear tumor margins surgeons use as ballpark to resect tumors,
causing damage to the patient. Although surgery has improved long-term survival
and reduced mortality, it is not a standalone solution. The state-of-art in cancer
treatment today is surgical resection followed by radiation and chemotherapy. Figure
1.1 illustrates the commonly used therapies of cancer treatment described below.
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1.1

Motivation
Chemotherapy, Radiation and surgery are three pillars of modern cancer treat-

ment. Chemotherapy usually involves systemic administration of one or more than
one anti-cancer drugs to kill tumor cells by binding to their DNA thus inhibiting
tumor growth and spread. It is often administered before or after surgical resection
of tumors. For malignant solid tumor treatment, wide varieties of anti-cancer drugs
are used. Major limitation of many chemotherapy drugs is that they aﬀect even the
healthy dividing cells along with rapidly dividing cancer cells resulting in severe and
often adverse side eﬀects such as vomiting, nausea, diarrhea, appetite loss and hair
loss. This lack of delivery precision gives an opportunity to develop tunable surface
electric charge drug payloads for localized delivery to tumor tissue [7]. The other major drawback associated with chemotherapy is the high average cost of drugs, which
exceed USD 100,000 per year [8], especially in the United States. New chemotherapy
drugs with tunable physical, chemical and electrical properties are attractive options
for targeted delivery to tumor sites. Radiation is an important treatment modality,
which destroys cancer cells by the physical act of ionizing radiation. With advancement in imaging and image-guidance techniques, computerized treatment planning
and an overall better understanding of radio-biology, it is estimated that nearly 40%
of radiation therapy contributes to curative treatment [9]. Although there are several mechanisms by which radiation kills cancer cells, the high-energy rays primarily inhibit cancer cell division by damaging its DNA. The most common radiation
therapy used in clinical setting is with external radiation, but for cancers where retreatment is necessary such as gynecological and prostate cancers, internal radiation
or brachytherapy is delivered via catheters in the form of seeds as radiation sources.
Although in practice since 1970s, Photodynamic Therapy or PDT has seen a lot of
use in cancer treatments primarily of skin cancer in recent years. PDT is a process
of introducing a photoactive drug (Eg: Photofrin) locally or systemically into the
environment of target tissue with abnormal cancerous growth and irradiating it with
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a light source to create cytotoxic species such as reactive oxygen species (ROS) that
destroy the cancer. With the establishment of a series of clinical protocols for the use
of photo-active drugs in the 1970s, PDT has become an alternate approach to tumor
destruction [10] [11]. It was widely successful for treatment of skin cancers, as it is
easy to expose the skin to light. However, deep-seated non-homogenous nature of
solid tumors limits the application of PDT. It is important to note that the chemical
action induced by PDT induces apoptosis of targeted lesions, active investigation is
under progress for deep-seated bulky solid tumors. The mechanism of tumor destruction or ablation in PDT is by light induced irradiation to create cytotoxic species,
and presence of oxygen accelerated this process, Fig 1.

Fig. 1.1. Modern cancer treatment modalities (a) Radiation therapy,
(b) Chemotherapy and more recently, (c) Photo Dynamic Therapy

1.2

Interventional methods of cancer management
Although most doctors treat cancers with surgery, radiation therapy and systemic

chemotherapy, depending on the stage of patients cancer, there are interventional pro-
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cedures [12] for treatment available now. In the case of primary or metastatic liver
tumors, interventions are used when there are uncontrolled symptoms from cancer,
deterioration of liver function or when there is increased tumor burden. Chemoembolization, Radioembolization and Tumor Ablation are three common interventional
procedures. These procedures though not curative, relieve the patients symptoms
and extend their survival.

1.2.1

Chemoembolization

Chemoembolization is a procedure where high concentration of medication [13]
placed in contact with the tumor for long periods of time (up to a month). The medication is injected into the artery feeding the tumor with a catheter. The advantage
of chemoembolization is no side eﬀects because of localized delivery of medication.

1.2.2

Radioembolization

Radioembolization is a targeted radiation delivery procedure where radioactive
beads [14] are injected into the arteries supplying the tumors. The beads are lodged
in the tumors and decay the radiation over a period of 2 weeks all the while destroying
the tumors. The advantage of this procedure lies in targeted radiation dose treatment,
which is safer than conventional radiation therapy.

1.3

Tumor Ablation
Tumor ablation techniques are minimally invasive techniques to destroy tumors

by heating or freezing to extreme temperatures or by the action of chemical substances [15]. In many cases, a special probe or implant is inserted into the targeted
tumor tissue using an image-guided procedure and the probe destroys the tumor by
ablative action. The ablative action can take place by means of thermal, electrochemical or RF mechanism. Implantable devices have been developed to treat cancers that
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occur in regions of the body that have diﬃculty of access to oncologic surgeons. Particularly, the cancers of gastrointestinal tract and some deep-seated organs such as the
liver and pancreas are good candidates where such devices have application. There is
an urgent need to develop implantable ablation devices because tumors metastasize
and recur after residual treatment. Surgery is not a viable option in case of recurrence. Microscale implantable devices that can be triggered wirelessly may be left in
the tumors using a needle biopsy and activated periodically. These devices may be
triggered multiple times to deliver ablation therapy and could remain inside for an
extended time with minimum maintenance. Implantable devices have been studied
since the past decade to treat cancers [16] [17]. The history of implantable devices for
cancer treatment however, is much older than that. In the 1980s, implantable radiators were designed for delivering microwaves following surgery to in vivo feline brain
for the treatment of glioblastoma [18], a deadly brain cancer that is surgically inaccessible due to its deep inﬁltrating nature. Plasmonic heating of intraperitoneal tumors
in mice were conducted using implanted near-infrared light sources [19] for treatment
of ovarian tumors. Bjorn Nordenstrom of Sweden pioneered several inventions for
direct current delivery to tumors and called it electrochemical treatment [20] [21] in
the 1990s. According to his observations, tumors are more sensitive to local changes
in their microenvironment and the ionizing species generated through direct current
electrochemical treatment destroy tumor tissue locally around the electrodes. More
recently, a localized drug delivery device for pancreatic cancer [22] was developed for
implantation directly into the pancreatic tumor to release pre-programmed drug dose
for a period of 60 days. With tumor ablation currently in use to treat several patients for whom conventional therapies have failed, it is important to understand the
state of art in ablation therapies. The next section describes several existing ablation
techniques, which are used by interventional oncologists and radiologists worldwide.
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1.3.1

Thermal Ablation techniques

Interventional techniques, particularly local targeted ablation of non-resectable
tumors is a viable option for most patients to improve their chance of survival. Ablation techniques are broadly divided into two categories, Thermal Ablation and NonThermal Ablation. The most common Thermal ablation techniques are RF Ablation [?], Microwave Ablation [], Laser Induced Thermal Therapy [26] and CryoAblation [28]. Irreversible Electroporation [30] and Electrochemical Ablation or Electrochemical Therapy [31] are Non-Thermal Ablation techniques which cause destruction
of tissue by formation of pores in the cell membrane and by the action of toxic chemical species generated due to direct current passage respectively. In the case of liver
cancer, in situ techniques such as RF Ablation and Microwave ablation are now becoming common in clinical practice and many oncologists are suggesting them to
patients. The aim of thermal ablation techniques for both primary and metastatic
tumors is to locally burn or ablate tumors by heating to destroy them. In this process a tumor margin of normal tissue surrounding the tumor mass is also ablated.
Ablation modalities are described below in detail.

Radio Frequency Ablation (RFA)
Radio Frequency Ablation (RFA) is a form of thermal ablation where the tissue is
destroyed by application of high frequency (3 30 MHz) RF pulses or electromagnetic
energy via a RF generator into a RF probe. The RF probe or electrode causes an
alternating electric ﬁeld in the tissue of the patient and the frictional heat generated
around the electrode increases temperature of the tumor tissue by up to 100C thus
destroying the tumor by irreversible cellular damage [23]. RF Ablation is in practice
carried out for 10 to 30 minutes and a temperature beyond 100C causes carbonization
around electrode tip.
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Microwave Ablation (MWA)
Microwave Ablation (MWA), introduced in clinical use since 1990s is a type of
thermal ablation where hyperthermia of tissue is created by exposing it to electromagnetic frequencies (915 MHz and 2.45 GHz) from the MW generator. High frequency
microwaves at 6GHz and 18GHz are also being evaluated theoretically for eﬃciency
[24]. Unlike RFA, where an electrical current is generated, MW energy in the form
of a propagating electromagnetic ﬁeld is generated to destroy tissue. Currently 12
MWA devices are commercially available for clinical use [25].

Laser Induced Thermo Therapy (LITT)
Laser Induced Thermo Therapy (LITT) or Laser ablation is a percutaneous form
of ablation in which laser energy is transmitted via optical ﬁber probes to cause tissue
destruction through coagulative necrosis [26] in well-deﬁned areas of internal organs.
Monitoring the thermal eﬀects is necessary in LITT and is usually carried out by
MRI. Usually Nd:YAG laser of 1064nm is used and it has a maximum output power
of 100W. Malignant tumor cells are more sensitive to heat because of their altered
metabolic state which produces hypoxia [27]. The above three forms of hyperthermic
ablation cause acute coagulative necrosis of aﬀected tissue, an irreversible damage to
cells through heat damage.

Cryo Ablation (CA)
Cryoablation (CA) or Cryotherapy is an hypothermic ablation procedure in which
tumor tissue is frozen by iceball formation at temperatures close to -190C. Cryoprobes
are precisely placed with real-time guidance by intraoperative ultrasound monitoring
into the tumor tissue. In clinical settings, a set of two freeze-thaw cycles is carried out
to ensure complete cell death from dehydration and osmotic shock. Liquid nitrogen
was commonly used as the cryogen but it has been replaced with Argon gas due to
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Fig. 1.2. Commercial thermal ablation probes for (a) RFA (b) MWA
(c) LITT and (d) CA

its advantage of rapid circulation through small probes (up to 17 gauge) and rapid
cooling to low temperatures. The major advantage of Cryoablation over other single
probe thermal ablation techniques is the ability to control the shape of the zone of
necrosis [28]. Commercially available ablation probes [29] [33] used in these ablation
techniques are shown in Fig 1.2 and the parameters used in Table 1.

1.3.2

Non Thermal Ablation techniques

Irreversible Electroporation (IRE)
Irreversible electroporation technique induces cell apoptosis or programmed cell
death by action of short pulses of strong electric current via monopolar electrodes to
form permanent nanopores within the cell membrane. Ablation eﬃcacy is determined
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Table 1.1.
Mechanism of action and operating parameters of thermal ablation techniques
Type of Ablation Mechanism of action

Parameters

RFA

Coagulative Necrosis

3 - 30 MHz

MWA

Coagulative Necrosis

915 MHz, 2.45, 6, 18 GHz

Laser Ablation

Coagulative Necrosis

3 - 10 W

Cryo Ablation

Coagulative Necrosis

-190 C

by number of pulses (n), pulse duration (t), distance between electrodes (d), and
voltage applied (V). There is no tissue heating or thermally induced eﬀects making
IRE an attractive treatment option for tumors close to the blood vessels and sensitive
structures. IRE has been successfully tested in clinical setting mainly for the liver,
pancreas, kidney, and lung cancers with emerging applications in the brain [23].

Fig. 1.3. Mechanism of cell death in Irreversible electroporation from
electric ﬁeld application to elimination by immune system

Electrochemical therapy (EChT)
Cancer cells are very sensitive to chemical changes in their microenvironment
[20] and in Electrochemical ablation or Electrochemical therapy [24] electric current
induces changes around electrodes inserted within tumors. The action of low voltage
induced electric current traversing living tissue produces local eﬀects at the points

10
of contact of the electrodes due to electrolysis of ﬂuid present in the tissue. The
formation of acid microenvironment around one electrode and basic microenvironment
around the other is the cause of ablative action in Electrochemical therapy. Several
other eﬀects are seen as a result of this electrochemical process. Electro-Osmosis,
which is deﬁned as the phenomenon by which molecules are transferred through a
porous medium inﬂuenced by the presence of an electrical current within a ﬂuid
medium, occurs. The migration of ions in the ﬂuid medium in which electrolysis
happens also results in the transport of the ﬂuid. This phenomenon is clearly observed
in a porous gel when current is passed. Fluid is transferred in electro-osmosis from
the positive to the negative electrode. It can be physically observed that the height
of ﬂuid rises at the negative electrode while it diminishes at the positive electrode.

1.3.3

Organization of the thesis

In Chapter 2, electrochemical treatments for tumor destruction will be discussed.
An implantable ultrasound triggered ablation device fabrication and its characterization for cellular ablation will be presented. Characterization of pH and electrochemical byproduct eﬀects on in vitro gel and ex vivo tissue will be presented. Chapter 3
will discuss the electrolytic systems for in vivo drug delivery through electrophoresis.
Design, fabrication and characterization of a novel ﬂuidic ﬂushable electrode system
for controlled drug delivery will be presented. Optimizing the ﬂushable electrode
system for electrophoretic movement of charged drug molecules in the brain will be
presented. In Chapter 4, the use of electrical impedance as a biomarker for distinguishing cancerous and healthy tissue will be presented. Ex vivo results characterizing
the impedance and current characteristics will be discussed. Chapter 5 will conclude
the thesis with a discussion on further research and development of electrolytic systems, characterization and optimization of a wireless device in a 3D phantom gel and
monitoring electrolytic ablation using MRI.
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2. ELECTROCHEMICAL TREATMENTS FOR TUMOR
DESTRUCTION
2.1

Introduction
A part of the work in this chapter has been submitted with the title ’Charac-

terization of an ultrasonically powered electrolytic micro-device for cellular ablation’
to Sensors and Actuators A: Physical journal. Electrotherapy of tumors involves
the passage of direct electric current through locally inserted electrodes for tumors
as a relatively safe, direct and eﬀective cancer treatment. More commonly known as
Electrochemical Therapy (EChT), as the name suggests creates extreme electrochemical changes in the environment around the electrodes through pH change. Although
there are uncertainties in the mechanism by which EChT destroys tumors, it has been
applied for the treatment of primary lung cancers in clinical studies conducted by the
famous Swedish radiology professor Björn Nordeström in the 1970s. He discussed
extreme pH changes as a possible mechanism of tumor destruction among many others such as electro-osmotic water transport, electrophoresis and ionic transport [25].
In EChT, the tissue acts as a conducting medium for passage of current, causing
electrolysis of tissue water at the electrode-tissue interface to produce chemical compounds, extreme pH change, nascent chlorine and hydrogen, which create a toxic local
microenvironment and destroy the tumor tissue.
The main components in an electrolysis process are the electrolyte (medium) for
current passage or charge ﬂow, the conducting electrodes cathode (negative electrode)
and anode (positive electrode) and a direct current power supply to provide energy
to the ﬂowing electrons. A minimum potential diﬀerence of 1.229V [27] between electrodes is suﬃcient to start electrolysis of water. The current generated thus drives
electrons from the cathode to anode and result in formation of H+ ions and oxygen at
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Fig. 2.1. Electrochemical reactions in tissue around cathode and anode [26]

the anode and formation of OH- ions and hydrogen at the cathode per the equations
shown below and in Fig. 2.1:
At the Anode, 2 H2 O ←−→ O2 + 4 H+ + 4 e –
At the Cathode, 2 H2 O + 2 e – ←−→ H2 + 2 OH –

As a result, the region surrounding the anode become strongly acidic (pH <7) whereas
the region around the cathode becomes strongly alkaline (pH >7). The anti-tumoral
eﬀect of electrolytic ablation was discussed in several in vitro and in vivo animal
studies with the number of such studies growing in recent years [28] [29] [30] [31].
Electrolytic ablation treatment has several advantages i) low cost, ii) minimal invasiveness, iii) localized eﬀect and iv) possibility of large volume treatment. In recent
years, with a growing interest in understanding how the biological destruction of cells
occurs in electrotherapy, several mechanisms have been proposed to explain the action
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of electrolytic ablation treatment . Most researchers agree that pH changes caused
due to electrolysis of tissue water is an important mechanism of ablation. To study
the pH eﬀects, we used an experimental approach to assess the pH ’fronts’ around
the cathode and anode separately in the same setup using time-lapse photography.

2.2

Phantom gel preparation
To observe the change in pH, a colorimetric measurement method was employed.

To mimic the electrical and mechanical properties of a tissue where electrolytic ablation would take place, we used a 0.2% (w/v) agarose gel pH with its pH adjusted
to 7.4, normal body pH. Agarose gel has advantage of being mechanically stable at
room and physiological temperature and electrically neutral with the ability to manipulate its conductivity. To mimic the electrical conductivity of a human organ, in
this case the brain, we added sodium chloride at a concentration of 0.75mg/ml [32] to
the agarose gel as it set. Further, to visualize the pH changes around the electrodes
in the gel, we added pH indicators (60 ul of Phenolphthalein dissolved in ethanol and
80 ul of Methyl Red dissolved in water per 30 ml agarose). Phenolphthalein (phph)
is an acid indicator that turns yellow below a pH of 6.8 and dark pink above pH 8.2.
Methyl red is an alkaline indicator that turns red below a pH of 4.4 and yellow above
pH 6.2.
The recipe for making the phantom gel may be modiﬁed depending on the volume
of phantom desired. We used a 50 ml phantom gel to allow suﬃcient depth for insertion of electrodes to simulate real tissue implementation. The extent of electrolysis,
which can be measured as the volume of region around each electrode (also called the
ablation zone) up to which the chemical species diﬀuse, depends on the length of time
for which the current is passed and the intensity of current. Higher current generated
due to greater dc voltage between electrodes increases the rate of electrolysis resulting
in growing rapidly ablation zones.
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Fig. 2.2. In vitro agarose gel setup for ablation characterization

Table 2.1.
Recipe to prepare a phantom gel for ablation characterization
Ingredient
Agarose
NaCl
HCl

Concentration
0.2% w/v
0.75 mg/ml

Purpose
Mimic mechanical stiﬀness
Mimic electrical conductivity

To achieve pH 7.4 Mimic physiological pH
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In order to test the rates of ablation zone progression around the electrodes, we
applied a potential diﬀerence of 4V (using a direct power supply) between two Pt
wire electrodes placed 2 cm apart in the 5 mm thick 0.2% (w/v) agarose gel.
We captured an image of the gel 30 minutes after the current started, Fig 2.2.
pH values around each electrode (anode on the right and cathode on the left) were
measured using a sharp pH probe embedded in a syringe needle and marked on the
image.

Fig. 2.3. Image of color change of pH-sensitive indicator in the agarose
gel around cathode (left) and anode (right)

2.2.1

Chemical reactions in the phantom

The reddish colored ring around the anode is due to methyl red (turns red below
pH 4.4), which is also conﬁrmed when we measured a pH of 2 around the anode using
the pH probe. Acidic pH around anode can be explained due to H+ ion migration to
the anode, combining with Cl- to form hydrochloric acid (HCl) or due to the formation
of hypochlorous acid (HOCl). At the cathode, a dark pink to fuchsia colored ring seen
due to phenolphthalein (turns pink above pH 8.2). The values of pH measured around
the cathode were 12 in the alkaline range due to combination of sodium ions Na+
and hydroxyl ions OH- formed during electrolysis. These ionic species are responsible
for cellular necrosis in real tissue, however the rate of reaction determines which ionic
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species causes tissue damage. Due to radially outward concentration gradients from
the electrode and applied potential gradient, diﬀusion of these ionic species increases
the necrosis zone. These biochemical eﬀects were observed in the in vivo studies done
on dog livers by Li et al. [21].
Other eﬀects were observed when the intensity of current was increased and when
current is passed between the electrodes for an extended period. We observed water
migration from anode to cathode, through electro-osmosis. This caused local hydration in the region around cathode and local dehydration around the anode. Due to
presence of salt in the body, an additional chemical reaction that occurs at the anode
is the liberation of Chlorine, a strong oxidant, which causes lethal injury to cells in
the microenvironment around the anode. Hydrogen gas is liberated at the cathode,
which causes local cavitation of the tissue [20]. The toxic properties of chlorine at
the anode and a broader zone of hydrogen chloride action explain the mechanism of
action of Electrolytic ablation [33].

2.2.2

Quantifying chlorine zone

In order to conﬁrm and quantify the generation of chlorine around the anode,
100uL of 10% potassium iodide solution (1gm of KI in 10 ml of de-ionized water),
was added to the 0.2% (w/v) agarose gel. Pt electrodes with 1 mm of tip exposed
and the rest insulated by parylene-C coating with 5V applied between them are used
for electrolysis. Current monitored on the power supply shows a constant 1.1 mA
throughout the 30 minutes of treatment. Potassium iodide in the gel consumes the
chlorine, which is only generated at anode to produce iodine according to the chemical reaction (3) shown below. Iodine is seen as a brown precipitate around the anode
with its concentration increasing with time, Fig 2.4a. An ex vivo section of bovine
liver obtained two hours post slaughter from the abattoir was soaked in a container
with potassium iodide (KI) solution for 30 minutes. The ring of iodine formation on
the surface of the liver, around the anode after anodic electrolysis where chlorine is
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generated, can be visualized in Fig 2.4b. A close up of the region where chlorine is
converted to iodine is shown in Fig 2.4c. This represents an image captured at 30 minutes after direct current treatment. Due to presence of several biological substances
and fat in the bovine liver section, we see a smaller brown ring when compared to
the transparent agarose gel phantom section.

2 KI + Cl2 −−→ I2 (brown) + KCl

Fig. 2.4. Chlorine generation seen through iodine formation as a ring
only around the anode in a phantom agarose gel (a) and a bovine
liver section soaked in potassium iodide (b), 30 minutes after current
treatment was started. Close-up showing diameter of chlorine ring
(c).

Progression of the circumference of chlorine diﬀusion in the phantom gel was
captured via time-lapse photography every 60 seconds for 30 minutes. Although
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iodine is released by reacting with chlorine, it is an indirect measure of chlorine
generated at the anode with time. Diameter of chlorine front was measured in agarose
gel, displayed in Fig 2.5 below. As voltage was increased, with application of 15
V dc between electrodes, we observed the circumference increase to 15 mm at 30
minutes. Visualization of chlorine generation inside the body is possible by perfusion
of agents like potassium iodide into the tumor to observe progression of treatment.
With advanced imaging modalities, it is also possible to obtain contrast to iodine
generated around the anode.

Fig. 2.5. Progression of anodic chlorine front with time in phantom agarose gel

2.3

Wireless powering schemes
For devices that are implanted within the human body, reliable powering for long

durations is very important. Batteries used for powering implanted devices such as
pacemakers, are bulky, need replacement and have the risk of leakage of electrolytes.
Implantable microsystems with alternate power sources are required to mitigate battery lifetime problems. Power transfer via wireless mechanisms are attractive options
for clinical use by healthcare practitioners. They have the advantage of being trig-
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gered multiple times to deliver power from locations external to the body. Popular
wireless power transfer strategies are inductive, RF and ultrasonic. With advances in
microfabrication and nanotechnology, implantable medical devices are gaining popularity for treatment of patients with serious conditions such as ﬁbrillation, diabetes
and cancers. Implantable devices are also used for sensing and real-time monitoring
such as blood pressure, glucose, GI tract endoscopy, intramuscular electromyographic
(EMG) signals and for drug delivery in the form of smart pills and capsules. Implants must be as small as possible to allow painless insertion to reduce patient
trauma. Knowledge of the amount of power delivered to implants is crucial to prevent thermal damage to tissues and therefore it must be incorporated during implant
design. Understanding some of the issues faced by existing wireless power transfer
methods is important to design and develop newer formats of powering, particularly
for deep-situated implantable devices.

2.3.1

Inductive or near-ﬁeld powering

Inductive coupling has been utilized extensively for remote wireless powering of
implantable medical devices. An inductive power transfer system consists of two
coils, the transmitter and receiver coils, with the receiver coil integrated with the
implantable device inside the body. Voltage is induced on the receiver coil upon
application of a drive signal (sinusoidal current) to the transmitter coil, through
electromagnetic induction. This requires both the coils to be tuned to the same
resonance frequency. The power transfer eﬃciency with inductive powering depends
on alignment and coupling between the coils. Fig. 2.6a shows the inductive power
transfer scheme.

2.3.2

RF or far-ﬁeld powering

Electromagnetic power transfer is called RF power transfer if the coupling between transmitter and receiver is in the mid-ﬁeld or far-ﬁeld. Radio waves are in the
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(a) Inductive or near-ﬁeld powering

(b) RF or far-ﬁeld powering

Fig. 2.6. Common wireless power transfer methods

frequency range of 3 kHz - 300 GHz. Transmitted RF waves are omni-directional,
which signiﬁcantly aﬀects the eﬃciency due to loss of strength with distance from
the power source. Also, RF is known to present potential risks for human exposure
and output power is limited due to regulations [34]. High electromagnetic ﬁelds are
a form of ionizing radiation that damage the DNA and cause mutation, leading to
unnecessary eﬀects. RF power transfer scheme is depicted in Fig. 2.6b.

2.3.3

Ultrasonic powering

Wireless power transfer (WPT) using ultrasound is suitable for energizing and
communicating with deep-seated medical implants, eliminating the need for on-board
power sources,which require periodic replacement. Acoustic waves at ultrasound fre-
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quencies (>20kHz) are capable of propagating through the tissue and are safe to
use within the human body. Transducer elements (piezoelectric materials such as
PZT) employed in ultrasonic powering convert the input acoustic energy into electrical energy by physical crystal structure deformation. Resonance frequency of a
PZT transducer is determined by its thickness cut, where thin transducers vibrate
at a higher frequency than thick ones. PZT has a preferential emission of half wavelength ultrasound waves (speed of sound in PZT is 4000 m/s) from which its thickness
for a resonance frequency may be calculated. WPT through ultrasound can achieve
higher power density compared to RF and inductive power transfer for the same device size [35]. RF power transfer using transmit and receive antennas causes tissue
heating, is potentially risky for human use and inductively coupled powering needs
accurate alignment of coils and is eﬀective only at shorter distances.

Fig. 2.7. Block diagram of the micro-ablator powered by ultrasound

Fig. 2.7 shows the block diagram of the micro ablation device. Vs is the driving
voltage applied to the piezoelectric transmitter. Output voltage from the rectiﬁer Vo
is proportional to the acoustic input for the same distance along the central axis of the
transmitter. An ultrasonically powered micro-ablation device has the advantage of
minimally invasive insertion into tissue, for e.g. using a biopsy needle. Once activated
by an ultrasonic wave from an external transmitter, the micro-device generates a
direct current. This creates localized pH gradient through electrolysis of the tissue
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water to destroy the cancer cells. Ultrasonic powering dramatically miniaturizes
the device (mm-scale receiver), has deep penetration range ¿5 cm, and tolerant to
misalignment. One may trigger the micro-device multiple times to deliver ablation
therapy while it remains inside the tumor for an extended period with virtually no
maintenance.

Fig. 2.8. Micro-ablation device real-time implementation schematic
showing (a) biopsy insertion and (b) device activation via ultrasound
(720kHz)

2.3.4

Micro-ablation device

Implantable devices hold great promise for the future of cancer treatment. Devices
in the past for cancer treatment for e.g. a radiation micro-dosimetry [36] to monitor
radiation doses a tumor received, an IMOG or implantable micro-oxygen generator
[37] for in situ tumor oxygenation. In order to deliver electrolytic ablation to deepseated tumors in internal organs such as liver and pancreas, we characterized the
performance of an ultrasonically powered electrolytic micro-ablation device.

Design and fabrication
Fig. 2.8a shows a schematic of the micro-ablation device inserted into a deepseated solid tumor using a biopsy needle. Fig. 2.8b shows the ultrasonic wave activated device that generates ablation zones around the device due to changes in pH.
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Fig. 2.9. Fabricated prototype of micro-ablation device compared to a
standard United States penny, Device dimensions: 9mm 5mm 2mm

Fig. 2.9 shows a fabricated prototype of the device consisting of a piezoelectric receiver
(2x2x3 mm3̂ PZT) operating at its measured thickness mode resonant frequency of
720 kHz and surface-mount schottky-diode bridge rectiﬁer. Components are soldered
in place on a laser machined copper trace circuit layout. The bridge rectiﬁer converts
the PZT receiver alternating current (AC) output into direct current (DC) voltage
and supplies to the load. The DC voltage is applied to two platinum electrodes (0.5
mm diameter x 10 mm length, Anomet Products) for electrolysis, causing a change in
local pH. The electrodes are placed 20 mm apart to allow signiﬁcant ablation volume.
ˆ 200 mg), with 3.14
Overall device dimensions are 9 mm 5 mm 2 mm (90 mm3,
mm2̂ active surface area at the platinum electrode tips for current delivery to tissue.
The fully assembled micro-device is coated with 5 m parylene-C for passivation and
biocompatibility.

Experimental setup
The change in pH around each electrode occurs in an ablation zone, deﬁned as the
region up to which the chemical species diﬀuse, depends on the duration of time for
which we activated the micro-device. Rapid outward radial advancement of ablation
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zones occurs when current delivery increases the rate of electrolysis. Fig. 2.10a shows
the schematic of the experimental setup used to record the ablation zones caused of
pH change due to the micro-ablation device. To power the micro-device, a function
generator (3320A, Agilent) connected to a Class A RF power ampliﬁer (ENI A300,
300kHz to 35 MHz, 300W, 55 dB, E&I Ltd., NY, USA) supplied the drive voltage to a
2 mm thick PZT transmitter. Acoustic outputs from the transmitter were veriﬁed to
be lower than peak FDA-allowed intensity (7.2 mW/mm2̂) [38]. We placed the microdevice within a 0.2% w/v agarose gel along the axis of the PZT transmitter, 1 cm from
its surface, to achieve maximum power transfer eﬃciency. Acoustic power transfer is
usually studied in water (Z = 1.48 MRayls) because of its similar acoustic impedance
with tissue (Z = 1.58 to 1.7 MRayls). We used Agarose as a tissue phantom because
of its close acoustic impedance to liver. Table 2.1 shows the acoustic properties of
various tissues and some common materials used for acoustic transmission.
Table 2.2.
Acoustic properties of common transmission materials
Material / tissue

Z (in MRayls)

c (in m/s)

PZT

30 - 40

4000

Agarose

1.52 - 1.76+

1498 - 1600+

Water at 20 C

1.48

1480

Air

0.0004

330

Liver [39]

1.55 - 1.85

1595

Brain [40]

1.63

1540

Bone [41]

5.3 +/- 0.4

3476

We used a standard voltage meter to measure the rectiﬁer output voltage (V0
= 3.5V, 3.7V and 3.9V) under three separate acoustic inputs. In order to measure
ablation zone progression over time, we applied a rectiﬁed output of 4 V between the
two platinum electrodes placed 20 mm apart in the 0.2% (w/v) agarose gel. Figure
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2.10b shows the in vitro set-up. We used time-lapse photographs and measured the
ablation zone expansion from its circumference.

(a) Schematic of experimental setup

(b) Original experiment setup

Fig. 2.10. Recording the ablation zone using micro-ablation device
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2.4

Ablation characterization

2.4.1

Direct power supply

Initial characterization was conducted using a standard laboratory power supply
at several dc voltages (3V - 7V) to study the eﬀect of supplied current at various
voltages and circumference of ablation zones. The setup of characterization consists
two parylene-C coated Pt wire electrodes with an exposed active area 0.196 mm2̂
(0.5 mm diameter x 1 mm height). The electrodes are placed 20 mm apart in a
pH-indicator loaded 0.2% (w/v) agarose gel whose composition was described earlier.
Direct current was applied between the electrodes for 60 minutes. Time-lapse images
were captured every 60 seconds during electrolysis. This enabled visualization of
ablation zone expansion in real time. The radial expansion we observed showed that
electrode geometry plays an important role in the shape of ablation zone. Shape of
ablation zone may not be radial due to diﬀerence in electrical property of tumor and
healthy tissue. Analyzing the image data to calculate circumference, graphs showing
the extent of ablation (pH fronts) were generated for regions around the cathode and
the anode, Figure 2.11(a-b). Measured current proﬁle at speciﬁc dc voltage values
3V to 7V from the power supply show an increasing trend with time in proportion to
the rate of electrolysis, Fig. 2.12.

2.4.2

Ultrasound-generated voltage

Three distinct voltages (3.5V, 3.7V and 3.9V) were applied between the Platinum
electrodes of the micro-ablation device. Ablation was carried out for 30 minutes and
the circumference of pH zones around the cathode and anode was graphed. We used
an ammeter to record the current delivered at these voltages as a function of time.
Measured current levels are proportional to the voltage applied between the electrodes, shown in Fig. 2.13a. Current values measured with the micro-ablator device
are ten times lower (in the 0 to 1 mA) than those measured with a conventional lab-
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(a) Cathodic circumference

(b) Anodic circumference

Fig. 2.11. Circumference of pH fronts using direct power supply
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Fig. 2.12. Current delivered as a function of time with applied voltage (3 - 7V)

oratory dc power supply (1 to 10mA). Low current delivery is advantageous because
it doesn’t generate heat that damages the tissue. This allows the use of implantable
micro-ablator to perform tumor ablation close to large blood carrying vessels, as the
change in temperature during ablation is minimal. Heat generated with at two different voltage levels applied to the gel using direct power supply is graphed in Fig.
2.13b. When compared to thermal ablation techniques (which deliver an average
power of 100W in 2.5 minutes treatment in an ex vivo study [42]), the local change in
temperature from electrolytic ablation is negligible and not the main mode of cellular
destruction.
When we measured the pH front advancement around the cathode and anode, we
found an increasing trend in both the cathodic and anodic fronts, Fig 2.14(a-b). The
anodic front is seen to advance faster than the cathodic front, as has been observed

29
in a study by Rubinsky et al [43]. This indicates electrolysis occurring in the pHindicator loaded agarose gel, a voltage at the level of 3.5 V to 3.9 V, the maximum
rectiﬁed voltage that could be output from the micro-ablation device.

Current delivery analysis
At 3.5V, the current started at 0.256mA at 0 min and reduced to 0.24mA at 20
min to 0.228mA at 45 min. This shows a gradually decreasing trend at the same
voltage, indicating that agarose gel acts as a time-varying resistive load. At 3.7V, the
current started at 0.56mA at 0 min and reduced to 0.545mA at 20 min and increased
back to 0.56mA at 45 min. This implies a variation in current of 0.02mA. At 3.9V,
the current started at 0.75mA at 0 min and had ﬂuctuations up to 0.8mA and reduced
back to 0.75mA at 20 min. A sudden jump in current to 0.87mA at 21 min continued
and followed by a ﬂuctuating trend. The current gradually settled to 0.83mA at
45 min. The surge at 21 min is due to the rapid electrolysis rate. The microscale
electrolytic gas bubbles at the anode coalesce to form larger bubbles, temporarily
occluding the active Platinum electrode area. This momentarily drops the current.
Once the bubble diﬀuses through the agarose gel, current increases to its previous
stable value. Comparing current delivery at 3.5V and 3.7V, the current is stable and
less variable at 3.7V. Comparing current delivery at 3.5V and 3.9V, the current at
3.5V is free from ﬂuctuations. Comparing current delivery at 3.7V and 3.9V, the
current at 3.7V is relatively stable and could be used to plan treatment doses.
We suggest operating the micro-ablation device at 3.7V to allow stable current
delivery and obtain uniform ablation zone volumes. However, minor variations in
current are to be expected. For all practical purposes the currents delivered from
the micro-ablation device are at safe level and the device can be used to treat deepseated tumors locally, eﬀectively and safely. For all three voltages, current magnitudes
delivered to the gel are between 0.1 and 1 mA for 45 minutes indicating a safe level of
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operation of the device. The threshold for direct current shocks longer than 2 seconds
is 150 mA [44].

Ablation zone analysis
Video camera images were captured for visual tracking of pH fronts for the entire
duration of ablation (45 min). The images were processed and analyzed using ImageJ
software to calculate the circumference of pH fronts around the anode and the cathode. Figure 2.14a and 2.14b show the pH fronts around the cathode and the anode,
exhibiting a generally increasing trend with time.
Anodic pH fronts: At 3.5V, the anodic pH front circumference at 5 min was
9.06mm. It steadily increased to 15.6mm at 25 min and to 19.37mm at 45 min. At
3.7V, the pH front circumference was 16.12mm at 5 min and increased at a rate of
0.8mm/min to 24.22mm at 15 min. After 15 min, it increased steadily at 1mm/min
to 31.59mm at 45 min. At 3.9V, the pH front circumference was 17.11mm at 5 min
and increased rapidly at a rate of 0.8mm/min to 25.29mm at 15 min. After 15 min,
the circumference increased 2mm for every 5 min and the circumference was 37.89mm
at 45 min. The trend of rapid increase in anodic circumference followed by a steady
increase is logarithmic in nature. The average rate of circumference at 3.5V is 0.258
mm/min, at 3.7V is 0.387mm/min and at 3.9V is 0.519mm/min. The anodic pH front
circumference ﬁt a logarithmic curve for all three applied voltages (R-squared values
for 3.5V, 3.7V and 3.9V are 0.9831, 0.9901 and 0.9833 respectively). Comparing 3.5V
and 3.7V, there is a 7.06mm diﬀerence in the circumference at 5 min. Between 3.7V
and 3.9V, the diﬀerence in circumference is 0.99mm.
Cathodic pH fronts: At 3.5V, the cathodic pH front at 5 min was 5.29mm and
linearly increased to 10.74 mm at 45 min. At 3.7V, the circumference was 6.02mm
at 5 min and doubled to 12.27mm at 25 min. After 25 min, the rate slowed down,
and the circumference increased only by 2.54mm to 14.81mm at 45 min. At 3.9V,
the circumference was 8.27mm at 5 min and linearly increased to 15.91mm at 45 min.
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(a) Current delivered to the gel from the micro-ablation device

(b) Power loss (heat generated) at 3 V and 4V

Fig. 2.13. Current delivery with micro-ablation device and heat loss comparison

32

(a) Cathodic circumference

(b) Anodic circumference

Fig. 2.14. Circumference of pH fronts using micro-ablation device
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The average rate of circumference at 3.5V is 0.136 mm/min, at 3.7V is 0.22 mm/min
and at 3.9V is 0.191 mm/min. Comparing circumference at 3.5V, 3.7V and 3.9V,
we notice a linear trend at 3.5V and 3.9V and logarithmic trend at 3.7V (R-squared
values for cathodic 3.5V, 3.7V and 3.9V are 0.9526, 0.9941 and 0.9837 respectively).
By comparing the trend for 3.7V between cathodic and anodic pH front circumference, we get a good ﬁt of the trend line to the data. R-squared values are 0.9941
for cathodic circumference and 0.9901 for anodic circumference. The applied 3.7V
indicates a coulomb dosage of 1.485C (0.55 mA for 45 min). The anodic front advances more rapidly (average rate: 0.387 mm/min) than the cathodic front (average
rate: 0.22 mm/min), as also observed by MRI image analysis by Meir, et al. [43]

2.5

In vitro study
We conducted an in vitro study to measure extent of ablation treatment outcome

through cell viability. Although in vitro cell suspension platforms are useful to determine cell viability using commercially available indicators and microscopy, they do
not provide an accurate representation of the in vivo tumor environment. Absence
of a structural foundation cannot suggest direct translation of the in vitro results
for treatment planning in vivo. In tissue engineering and cancer biology, cells seeded
within three-dimensional (3D) matrices such as collagen and matrigel are increasingly
being used to understand eﬀects of new treatments. 3D cell cultures are capable of responding to stimuli in a manner analogous to in vivo biological environment [45] [46].
Therefore engineering 3D tumor nodules in suspensions that mimic in vivo tumor
microenvironment can have direct clinical impact [47]. Suspension of human breast
tumor nodules (breast cancer cells (HMT-3522 S1)) grown in soft tissue-mimic matrices such as collagen and matrigel were treated using DC voltages. The in vitro tumor
nodules were incubated in complete media before applying treatment and conducting
a viability assay. Incubated cells were placed on a cover slip in a glass petri dish.
Fig. 2.15 shows the Platinum electrodes with 20 mm separation distance to match
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the agarose gel experiments. The active tip area was in contact with the cell culture
medium. pH change caused the change in color of the culture medium around the
electrodes.
Cell line description HMT-3522 S1, is a sub cell line that has been derived
from human mammary epithelial parent cell line HMT-3522. HMT-3522 was established from a benign breast tumour of a 48 year old woman and has undergone spontaneous malignant transformation. HMT-3522 S1 subline consists slow proliferating
non-neoplastic breast epithelial cells.

Fig. 2.15. Breast cancer cells treated using 5V for 30 minutes, applied
between platinum electrodes, 20 mm electrode separation

2.5.1

Cell viability assay

DAPI (4’,6-Diamidino-2-Phenylindole, Dihydrochloride) is a biomolecular probe
that diﬀerentiates living and dead cells in vitro. DAPI dye will only stain dead cells
and penetrates poorly into cells with intact cell membrane. To prepare a 300 nM
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DAPI stain solution, 2 mL of deionized water or dimethylformamide (DMF) is added
to the entire contents of the DAPI vial and sonicated thoroughly to dissolve and make
a 14.3 mM (5 mg/mL) DAPI stock solution. A 300 M DAPI intermediate dilution
is prepared by adding 2.1 L of the stock solution to 100 L PBS. The 300 M DAPI
is further diluted in PBS to make a 300 nM DAPI stain solution. Cells are ﬁxed
using 4% paraformaldehyde. To label the ﬁxed cells a) wash the cells in PBS, b) add
enough 300 nM DAPI to cover the cells, c) incubate cells for 1-5 minutes without
light exposure, d) remove the stain solution, e) wash the cells 2-3 times in PBS and
f) image the cells using ﬂuorescence microscope. Results from our initial studies with
in vitro breast cancer cell culture are shown in Fig. 4.1, DAPI staining of non-treated
and (h) treated breast cancer cell (HMT-3522 S1) with direct 5V dc for 30 minutes.
The percentage of apoptotic cells after treatment were approximately 7 folds higher
than the control indicating the pH-induced ablation.

2.6

Limitations of electrolytic ablation
The limitation of Electrolytic ablation is the need to apply treatment for long time

(3 to 4 hrs) in order to destroy large tumors greater than 5 cm diameter. In a case
study for a patient with non-resectable liver tumor 4.2 cm x 4.2 cm x 2.6 cm (tumor
volume: 54.3 cm3̂) treatment with electrolytic ablation took 4.5 hrs to complete [48].
Although a marked reduction in tumor mass was observed, such long treatment times
might cause discomfort to patients. The insertion of an implantable device, such as
the one presented here, inside the tumor, with periodic wirelessly triggering, would
make it possible for electrolytic ablation to become an outpatient procedure. The
challenge of real-time monitoring is actively being addressed by close-loop systems
with treatment and telemetry functions for bi-directional communication within the
same implant [49]. There is need to develop the electrolytic ablation technique and
also miniaturize the device so multiple micro-ablators may be placed. This would
generate large size ablation zones for large tumors and reduce treatment time due to
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(a) Control (no treatment)

(b) After 30 minute ablation treatment

Fig. 2.16. Fluorescent images after ﬁxation with 4% paraformaldehyde and staining of S1 nuclei with DAPI
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multiple device activations. Another challenge that need to be addressed is the need
for feedback from the PZT receiver about the state of the tumor showing the extent of
tumor ablation. This information is crucial because it decides the length of treatment.
Ablation for lengthy durations (beyond 4-5 hrs) lead to burning and charring of tissue
and may damage surrounding healthy tissue and organs if not properly controlled.
Fractionated treatment such as used in radiation therapy is an option to consider in
order to divide the dosage of ablation for multiple sittings. In addition to causing
local change in pH to destroy tissue through toxic chemical species, electrolytic eﬀects
could be used to transport charged drugs from the surface to deeper regions of tissue.
A DC electric ﬁeld exists in the medium between the electrodes. The electric force
exerted by this ﬁeld could move charges. This is possible by application of low voltage
DC between electrodes inserted in a tissue and injecting a charged drug in between
the electrodes. Due to transport of ions in tissue under the inﬂuence of electric
ﬁeld, the charged drug also gets transported. The distance advanced by the drug
is proportional to the magnitude of charge and duration for which the electric ﬁeld
is applied. This technique is widely used in biochemistry to separate proteins of
diﬀerent sizes based on their charges, called gel electrophoresis. When applied inside
the brain, it is called in vivo brain electrophoresis [50]. Recent ﬁndings from in vivo
brain electrophoresis suggest the transport of a MRI contrast agent Gadopentetate
Dimeglumine (Gadolinium) in live canine brain with the application of DC voltage
between electrodes. The contrast agent movement was demonstrated using Magnetic
Resonance Imaging (MRI). Due to the need to develop novel ways to increase local
concentration of drugs in brain tumors, we explore this technique and ﬁnd ways to
optimize the drug transport, addressing its implementation in Chapter 3.
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3. ELECTROPHORETIC DRUG DELIVERY SYSTEM
The work in this chapter has been published with the title ’Fabrication and characterization of implantable ﬂushable electrodes for electric ﬁeldmediated drug delivery
in a brain tissuemimic agarose gel’ in Electrophoresis journal [51]. Local drug delivery methods are attractive options that supplement systemic delivery. In the case of
cancers, they facilitate cytotoxic drug delivery directly to the site of the tumor and
achieve signiﬁcant therapeutic concentrations in a controlled manner. Although diffusion limitations exist for local deliveries, using electric ﬁelds to propel drugs in the
local tumor environment using techniques such as electrophoresis and iontophoresis
can elevate spatial drug distributions. Large drug distribution volume is especially
important for cancers of the brain (e.g. Glioblastoma Multiforme) which have unpredictable tumor margins and cannot be completely eliminated through surgical
resection. Electrophoresis or iontophoresis techniques can overcome the limitations
of drug diﬀusion by forces of electro-migration and electro-osmosis and achieve potentially controllable and large spatial distribution volumes. New device platforms
based on the technique of electrophoresis for transport of charged drugs have the
potential to become a new mode of anti-cancer therapy. To test the proof-of-principle
requires extensive testing and validation of electrophoresis in models of the brain in
vitro as well as in vivo. Identifying and optimizing key electrophoresis parameters
for surgical planning through novel electrodes oﬀers a new modality for treatment of
brain tumors.

3.1

Drug Delivery in the Brain
Drug delivery to the Central Nervous System (CNS) poses signiﬁcant challenges

due to the presence of Blood-Brain-Barrier (BBB). Although there are numerous
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promising drugs that potentially help patients suﬀering with CNS pathologies, getting
these drugs past the BBB remains a daunting task. The BBB is mainly permeable
only to substances with molecular mass ¡ 500 Daltons and high lipid solubility [52].
Many drugs that could theoretically be used for chemotherapy of brain cancers are
unsuitable for clinical use due to poor penetration into the CNS and systemic toxicity.
Novel techniques to deliver high concentration of therapeutic substances to the brain
will be beneﬁcial to treat a variety of brain ailments, including brain tumors such as
Glioblastoma Multiforme (GBM).

3.1.1

Interstitial drug delivery through Controlled Release polymers

Two techniques tested over the last 10-15 years have been controlled release (CR)
exempliﬁed by the Gliadel Wafer and convection-enhanced delivery (CED). Slowrelease polymer matrices carrying chemotherapeutic drugs surgically implanted into
tumor resection cavity are attractive options for treatment of Gliomas. Drug diﬀusion
rate from the polymer matrix depends on the diﬀusion properties of the drug and the
permeability properties of the polymer [53]. Development of novel therapies such as
viral-gene therapy, immunotherapy would allow combination therapies for drug release
using these polymers. Although interstitial delivery through CR has advantages such
as low systemic toxicity and protecting the drug from degradation, its main drawback
has been poor penetration due to the presence of BBB, which has limited their clinical
utility [54]. Clinical trials have shown only a marginal survival advantage for GBM
patients receiving GW up-front [55]. Figure 3.1 shows the insertion of GW into a
cavity within the brain parenchyma, post-resection.

3.1.2

Convection-enhanced delivery

It is possible to transport drugs into the brain interstitium by applying pressure gradient during interstitial infusion, called convection-enhanced delivery (CED).
Pressure gradient is the diﬀerence between skull pressure and the infusate injection
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Fig. 3.1. Controlled release through surgically implanted Gliadel wafer [54]

pressure. This gradient causes convection and has the potential to enhance distribution of small and large molecules to achieve drug concentrations greater than systemic
levels. Infusion of drugs is performed through inserted infusion cannulae connected
to syringe pumps. Volume of distribution in CED is a complex function of several
parameters like the infusate ﬂow rate, catheter placement, size, design, infused volume and brain geography. The main drawback of CED, however, in addition to poor
penetration, has been a rather unpredictable and uncontrolled drug distribution [56].
Clinical trials have shown no survival advantage for patients receiving CED versus
GW at ﬁrst tumor recurrence [57]. Fig. 3.2 compares the drug distribution with
diﬀusion and convection, clearly indicating a larger volume of infusate distribution in
CED.

3.1.3

In vivo Brain Electrophoresis

A controlled way of achieving high drug concentration near the brain tumors is
necessary. Since it is known that charged substances move under the inﬂuence of
an electric ﬁeld; using this principle, a technique called in vivo brain electrophoresis has been employed to address some of the limitations of CR and CED. In vivo
brain electrophoresis is a process in which a charged substance injected into the
brain parenchyma is moved in a predictable/controllable way in a sizable and scal-
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Fig. 3.2. Convection-enhanced delivery showing drug distribution proﬁle larger than diﬀusion proﬁle [58]

able volume of interest by an electric ﬁeld created by implanted microelectrodes. In
vivo brain electrophoresis has been successfully tested in the brains of living canines
(beagles), moving negatively charged Gadopenteate Dimeglumine (Gadolinium) in a
predictable way according to the applied Direct Current (DC) ﬁeld [50]. Fig. 3.3
shows the intra-operative view of implanted electrode array plate. Assessment of
Gadolinium electrophoresis was done by MRI scans and histopathology studies.

3.2

In vitro electrophoresis study
To develop suitable electrodes for brain electrophoresis, we wanted to understand

the parameters and mechanisms involved under diﬀerent current deliveries. We conducted several in vitro studies using brain phantom gels to study a) the extent of
electrophoresis that could happen with time, b) the current that is delivered, c) the
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Fig. 3.3. Intra-operative view of in vivo brain electrophoresis experiment [50]

eﬀect of increasing the drug concentration after initial electrophoresis, d) the eﬀect
of electrode geometry (wire electrodes versus can electrodes / depth electrodes and
mesh electrodes), e) eﬀect of adding insulation, f)eﬀect of electric ﬁeld by modifying
separation between electrodes and voltage applied between electrodes.
Initial studies were done with highly charged dye Evans blue (q: -4). Next, a
chemotherapeutic substance shown to be active in vitro against GBM but unable to
cross the BBB, Doxorubicin (q: -1) was studied. A list of putative charged drugs
active against GBM in vitro and their physiological charges (at pH 7.4) are listed in
Table 3.1. The maximum units of charge that the drugs possess are 2.

3.2.1

Electrophoresis of charged Evan’s Blue dye in Agarose gel

The tissue phantom/surrogate is a useful model to test the transport of drugs
in an environment with similar mechanical and electrical properties as a real human
tissue. We prepared agarose phantom gel with properties similar to the human brain,
as described in the chapter 2. Agarose gel phantoms are inexpensive, easy to prepare
and stable with the ability to tune their properties. Agarose gel allows straightforward
visualization of drug diﬀusion due to its transparency. However, a limitation of brain
phantom gels is the homogeneous and isotropic nature, which is deviant from the
complex physiological human brain composition, a limitation of this study.
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Table 3.1.
List of putative drugs active against glioblastoma in vitro and their
physiological (pH 7.4) charge
Drug

Physiological charge

Adriamycin

+1

Irinotecan

+1

Vinorelbine

+2

Mitoxantrone

+2

Vincristine

+2

Vindestine

+2

Vinblastin

+2

Methotrexate

-2

Bleomycin

+2

DTIC

-1

Lapatinib

+1

Mesh electrodes
In the initial experimental setup to observe movement of Evans blue (EB) dye, two
Platinum clad mesh electrodes (1 x 1) were inserted in a 0.2% (w/v) Agarose gel, with
70 mm electrode separation. Electrode on the left is the cathode and electrode on the
right is the anode. 10V dc was applied to the electrodes and 2uL of EB occupying a
diameter of 6 mm was placed between the electrodes, as shown in Fig 3.4(a-b). Metal
electrodes in direct contact with the agarose gel create bubbles due to electrolysis of
water content of the gel. As the voltage is increased, rate of electrolysis and bubble
generation increase.
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Fig. 3.4. Setup to measure dye displacement in phantom gel using
Platinum clad mesh electrodes (a-b) and Platinum depth electrodes
(c-d)

Fig. 3.5. Current through Platinum mesh and depth electrodes for
electrophoretic transport of Evan’s blue dye in Agarose gel
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Fig. 3.6. Displacement of Evan’s blue dye under applied electric ﬁeld
in Agarose gel- comparison between Platinum mesh and depth electrodes

Depth electrodes
Clinical Deep Brain Stimulation (DBS) electrodes or depth electrodes used in
treatment of epilepsy tumors were employed for electrophoretic transport of Evan’s
blue dye. The monitored current is shown in Fig. 3.5 as a solid line. The dye transport
distance using depth electrodes are plotted as solid lines in Fig. 3.5. The current
values measured when depth electrodes are used is lower due to lower active area
of contact available for electrolysis. The distance EB advanced toward the cathode
when depth electrodes are used, is smaller in comparison to distance advanced in the
case of mesh electrodes. The dye displacement with depth electrodes inserted in the
phantom gel at the beginning and 5 hours after treatment are shown in Fig. 3.6.
From a clinical standpoint, the depth electrodes are more suitable for insertion into
the brain for drug delivery as they may be placed within a catheter, which is not
possible for the mesh electrodes.

46

Fig. 3.7. Comparison of electrodes used for electrophoresis of EB with
the same applied voltage and electrode separation

Comparison of electrodes for EB electrophoresis
A comparison of various electrodes used in the electrophoresis of EB with the same
applied electric ﬁeld (0.143 V/mm) showed greater displacement in the case of mesh
electrodes followed by wire electrodes which was followed by depth electrodes, Fig.
3.7. The reason for greater displacement in case of mesh electrodes can be explained
by increased rate of electrolysis resulting in greater current ﬂow to transport EB
molecule. However, the diﬀerence in EB displacement between Platinum wire and
depth electrodes may be due to diﬀerent electrode area available for electrolysis.
Current was monitored continuously for 5 hours, Fig 3.8 and the transport distance
of the charged dye was plotted, Fig 3.4b. Due to a large area of contact between the
Platinum mesh and the gel, initial current was recorded as 28 mA but it decreased
over time to 10 mA at 5 hours. The reduction in current can be explained due to
formation of gas bubbles (by products of electrolysis) at the electrode surface reducing
the active area available for current conduction. We calculated a rate of movement
of EB towards the anode at 1.35 mm/hr.
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Fig. 3.8. Progression of drug towards cathode with time

3.2.2

Electrophoresis of Doxorubicin in Agarose gel

Electrophoresis of charged drugs is relevant clinically as these drugs are administered in real patient studies. Adriamycin (chemical name: Doxorubicin Hydrochloride
or DOX) carrying a +1 charge was used in the study. It is a non-liposomal formulation
that weights less than 500 Daltons and is proved to cross the BBB. Preparation of the
formulation of Adriamycin for experimentation involved dissolving 2.5 mg Adriamycin
powder in 20 L of non-polar solvent dimethyl sulfoxide (DMSO). With Platinum wire
electrodes placed 70 mm apart in the agarose gel, 10 V dc was applied from a conventional laboratory power supply. 20 L of DOX formulation was injected at the
center between the electrodes. For 6 hours, current was monitored and the distance
advanced by the colored and charged DOX was captured via time-lapse photography.

Current remained constant for the ﬁrst ﬁve hours of electrophoresis and dropped
to 7 mA in the last hour, Fig. 3.4d.
We measured the displacement of the DOX droplet from its initial position over
time. A faint trace of the drug had a net displacement of 12 mm in 6 hours, Fig
3.4e. The same experiment was conducted in 1.2% (w/v) gelatin matrix of the same
volume as agarose gel. There is displacement of the drug to a greater distance in
the agarose gel repeatedly compared to the gelatin matrix. The current measured
in gelatin showed a non-uniform proﬁle with a rise in the ﬁrst two hours and an
abrupt drop. This conﬁrmed that agarose gel is a much stable matrix for in vitro
electrophoretic drug transport studies and is used for all the future electrophoretic
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Fig. 3.9. current proﬁle under inﬂuence of a 0.143 V/mm applied electric ﬁeld

studies. It has been used for drug infusion studies involving Convection-enhanced
delivery for GBM.
Even with such measurements in the gel, the current is not stable when measured
over a long time period in vivo because of change in resistive property of the tissue [50].
In the gel, ﬂuctuations in current are attributed to rapid electrolysis resulting from
generation of hydrogen micro-bubbles around the cathode and oxygen micro-bubbles
around the anode. These micro bubbles block the active area of the electrode for a
certain period, coalesce together to form larger bubbles and detach from the electrode
surface. In this process, measured current is not reproducible in every experiment.
This greatly limits its applicability for in vivo studies. It is desirable to have a stable
current that can be delivered continuously for electrophoretic transport.
To address the issue of unstable current, we ﬁrst compared electrical impedance
in Agarose gel with similar electrical conductivity as tissue, phosphate buﬀered saline
(PBS) which has a pH 7.4 and an ex vivo bovine brain section. 5V dc was applied
between two platinum wire electrodes separated by 20 mm in all three cases. PBS
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Fig. 3.10. Displacement proﬁle of DOX under inﬂuence of a 0.143
V/mm applied electric ﬁeld

Table 3.2.
Electrical resistance in PBS, 0.2% (w/v) agarose and ex vivo bovine brain section
Sample

R in kΩ

Phosphate Buﬀered Saline

1.645

0.2% (w/v) Agarose gel with 0.75mg/ml NaCl

2.609

ex vivo bovine brain

24.277

has the least resistance (1.645 kΩ) or highest conductance, due to presence of ionic
species. Bovine brain section had the highest resistance (24.277 kΩ) due to presence
of fat tissue, cortical folds and cell-cell junctions. Measured resistance in Agarose was
at an intermediate level, between that of PBS and bovine brain. In a study by Lin
et al., the eﬀect of injecting saline into the tumor for electrochemical therapy was an
increased size of tissue ablation zone [59]. In our case, a higher starting current was
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measured in PBS ( 3 mA) compared to ex vivo bovine brain ( 0.2 mA) or agarose
( 1.9mA). Presence of PBS allows passage of more current and would enhance the
electrochemical reactions at the electrodes.

3.2.3

Motivation for ﬂushable electrodes

Capillary-embedded electrode setup
In order to obtain a stable current in the electric circuit and eliminate gas bubbles
generated at the Platinum electrodes, we designed a capillary-embedded electrode
setup with saline ﬂush in and bubble ﬂush out using a ﬂow pump, Fig 3.11. The inﬂow
and outﬂow rates were maintained at 10 ul/hr. In the capillary setup, the distance
between the electrodes is ﬁxed to 20 mm. 5V dc was applied between the electrodes.
A 2uL droplet of DOX formulation that occupied a surface diameter of 5 mm was
placed in between the electrodes on the agarose gel. Due to electrophoretic force, the
positively charged DOX (+1) moved 3.4 mm in 4 hours toward the cathode. This
movement is accompanied by radial diﬀusion of DOX in the gel. Current monitored
over the period of electrophoresis showed a ﬂuctuation by only 1 mA. A change in
the color of DOX from orange to purple as it approaches pH >8 has been reported
in literature [60] and we see it in our setup.

Validation of electrophoresis with capillary-embedded electrodes
In order to optimize the performance of electrophoresis with the capillary-embedded
electrode setup, we conducted a few studies.
I) To verify that the charge of DOX is preserved and not aﬀected due to electrophoresis, polarity of the electrodes was switched two hours after an initial movement of DOX towards the cathode, initially to the right side in the gel. After polarity
switch, the cathode is now on the left side of the gel, and we see a reversal of move-
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Fig. 3.11. Capillary-embedded electrode setup with ﬂow pumps running to ﬂush in PBS and ﬂush out electrolysis by product gas bubbles
(a) and progression of DOX using the setup (b)

ment in the opposite direction. This made us conclude that the anti-cancer drug
DOX HCl does not lose its +1 charge during electrophoresis.
II) To limit the current density by coating the Platinum electrodes with 5 um
parylene-C layer and having only 1 mm of exposed Platinum. The amount of gas
generated by electrolytic reactions depends on the rate of electrolysis, which in turn,
depends on the current per unit area of the electrode. Thus, with minimized area,
we see bubbles only from the Platinum part of the electrodes. Current monitored
continuously for nearly two hours is shown in Fig. 3.12.
III) Additional charge added after initial two hours of electrophoresis. In the human tissue mimicking agarose gel with the capillary-electrode setup, 2uL of DOX was
initially injected in between the two electrodes occupying a diameter of 5 mm. 5V dc
was applied between the electrodes. After two hours of electrophoresis, a displacement
of 2 mm towards the cathode was observed. At the two hour point, an additional 2
uL of DOX was injected at the initial point of injection. This increased the net charge
density of DOX in the gel and there is more charge available for electrophoresis. Total
partial charge of DOX under solvated condition (adding solvating water molecules to
DOX) was calculated as + 0.123 electrons [61]. An additional 1 mm displacement of
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Fig. 3.12. Current proﬁle when 5V dc was applied to two Parylene
coated platinum electrodes

doxorubicin occurred after the second injection. We continued electrophoresis for the
next 2 h. A moving average of the current signal (interval size: 16) was monitored
continuously for the entire 5 h duration and plotted in Fig. 3.13. The moving average ﬁlter removes the random high frequency white noise and maintains the sharpest
step response without compromising the sharpness of the edge. The rise increases
from between 1.5-2.5 mA to 2.5-3.5 mA due to the additional charge available for
transport, requiring a larger electrophoretic force.

3.3

Fluidic-Flushable electrodes
Electrolytic bubbles that occlude the active electrode area in contact with tissue

prevent current ﬂow and drug delivery in the brain present. This is a major impediment for the successful implementation of in vivo electrophoresis. It is lethal to
let microscale bubbles enter the brain due to their possibility of entering the blood
stream. It is therefore necessary to ﬂush them out of the system before they diﬀuse.
As an expansion to the capillary-embedded electrode setup described earlier, con-
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Fig. 3.13. Current proﬁle when 5V dc was applied to two Parylene
coated platinum electrodes and an additional 2ul of DOX was added

tinuous ﬂushable electrodes following a facile fabrication, provide a solution to this
problem.

3.3.1

Design and fabrication

Laser micro-machined implantable electrodes with integrated microﬂuidic channels allow the removal of continuously generated micro-bubbles and electrochemical
reaction byproducts. A schematic of the ﬂuidic electrode with polyimide tubing used
for continuously ﬂushing phosphate buﬀered saline is shown in Fig. 3.14a. PDMS, a
transparent soft polymer is used due to its bio-compatibility and ease of processing in
the desired shape. Fig. 3.14b illustrates the ﬂuidic electrodes implanted in the brain
for electrophoretically-mediated drug delivery.
For the fabrication of ﬂuidic-ﬂushable electrodes, two PDMS substrates were
bonded, one incorporating a groove for housing the Platinum wire electrode and
the other with two microﬂuidic ﬂush channels, Fig. 3.15. The fabrication starts
with laser machining acrylic molds to create electrode groove and microﬂuidic chan-

54

(a) Schematic showing implantable ﬂuidic-ﬂushable electrodes

(b) in vivo electrophoresis in brain using ﬂuidic-ﬂushable electrodes (not to scale)

Fig. 3.14. Fluorescent images after ﬁxation with 4% paraformaldehyde and staining of S1 nuclei with DAPI

nels, both 0.5mm in diameter, and subsequent PDMS casting. Platinum electrode is
then bonded in the central groove (1.57mm2̂ exposed surface area), and sealed with
a PDMS cover. A fabricated prototype of the electrodes had overall dimensions of
50mm x 5mm x 1mm, Fig 3.16(a-b).
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Fig. 3.15. Fabrication of the ﬂuidic-ﬂushable electrodes using laser
micro-machined acrylic mold and PDMS with ﬁnal embedment of
Platinum electrode

3.3.2

In vitro study

Characterization of the electrodes was done by inserting them into the brain tissue phantom (0.2% w/v agarose gel) whose electrical conductivity was adjusted to be
similar to the human brain. Separation distance was maintained at 20 mm by holding
them using clamps. In the real brain, these electrodes would be placed stereotactically by neurosurgeons with image-guidance. Syringe pumps were used to cyclically
ﬂush PBS through the inlet channel and carry the bubbles (electrolysis byproducts)
accumulated in the PBS solution through the outlet. One pump with dual syringe
capability was used to ﬂow saline while two other individual pumps connected to ﬂow
outlets withdrew the ﬂushed solution. The ﬂow rate was maintained the same for all
pumps to maintain uniform ﬂushing and prevent leaks into the gel.
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(a) A ﬂexible ﬂuidic-ﬂushable electrode

(b) Optical micrograph showing ﬂush channels

Fig. 3.16. Fabricated prototype of electrode, overall dimensions 50
mm x 5 mm x 1 mm, Scale bar: 0.5mm

Transport distance
Fig. 3.17 compares the transport distance of charged EB dye with time using
the ﬂushable electrodes shown in Fig. 3.16 (2 mL/h ﬂow rate) and using no ﬂow
rate. Since EB carries a greater electric charge and molecular mass (EB: 961 Da,
q=-4) than DOX (543 Da, q=+1) and force is proportional to charge, EB requires a
larger electrophoretic force than DOX. Thus, more current ﬂows through the gel for
EB. This increases the rate of electrolysis at the electrodes, which increases the rate
of generation of electrolysis gas bubbles. A higher ﬂow rate of 2 ml/h removes the
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Fig. 3.17. Transport proﬁle of charged Evans blue over time using
ﬂushable electrodes with 2ml/hr ﬂow rate (red) and control (black)

gas bubbles continuously and prevents the bubble nucleation that limits the active
electrode surface area, which limits the eﬃcacy of drug delivery. The continuous
ﬂushing introduced by these ﬂushable electrodes maintains a stable current, allowing
the charged dye to travel a distance eight times greater than the control.

Current delivered
Continuous ﬂushing eliminated the electrolysis bubbles and maintained a stable
current causing the charged dye to move a greater distance. Current delivered to
electrodes at diﬀerent ﬂow rates is shown in Fig 3.18. The graph shows nearly constant
current for non-zero ﬂow rates. These electrodes are suitable for transporting charged
drug into cavities of resected brain tumors while maintaining nearly stable current
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Fig. 3.18. Transport proﬁle of charged Evans blue over time using
ﬂushable electrodes with 2ml/hr ﬂow rate (red) and control (black)

throughout the process. Using electric ﬁeld to move a highly charged dye is a way to
assess the performance of the ﬂushable electrodes. However, more extensive testing
in realistic brain phantoms and in vivo studies will evaluate the success of this drug
delivery mechanism.

3.3.3

Ex vivo study

Bovine brain sample was obtained to study electrophoretic transport using capillaryembedded electrode setup. The setup was ﬁxed to the tissue in the white matter of
a sliced 10 cm section of the brain (working area: 6.25 cm2̂). The sample was placed
onto a glass petri dish for ﬁxing the capillary-embedded electrode setup (Platinum
electrodes placed within glass capillaries separated by 20 mm distance) at room tem-
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Fig. 3.19. Ex vivo brain with capillary-embedded electrode setup
(left) and injected EB dye along white matter tract (right)

perature. Evan’s Blue dye was injected before starting the voltage. Two diﬀerent
methods were tested, a) injecting the dye into the brain and b) placement of a drop
of dye on the surface. 5V dc was applied to the electrodes using a direct power supply
and syringe pumps were running at a ﬂow rate of 2 ml/h. Due to opaque nature of real
brain tissue, it is diﬃcult to monitor the progression of electrophoretic drug transport. Using specialized electrodes to determine the charge density of a section of the
tissue would enable indirect monitoring of charged substance transport in the brain
due to electrophoresis. Sensors that measure impedance could be embedded onto the
ﬂushable electrodes to determine the diﬀerence between areas of tissue where there
is increased charge density due to drugs compared to areas where there is no charge.
To better understand the properties of a tissue that could aid in the development
of more realistic tissue phantoms, in Chapter 4, we measure the impedance, current
delivered and pH in the ex vivo brain. Characterization of impedance at diﬀerent
frequencies, electrical current delivered into the brain at applied dc voltage and pH
at discrete points within the white matter of the brain will be presented.
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4. MEASUREMENTS OF IMPEDANCE, PH AND
CURRENT IN EX VIVO BRAIN
4.1

Electrical property measurement in brain tissue
Electrical properties of tissues have been under investigation since the 1950s, when

Schwan et al. reported the conductivities and dielectric constants of dog tissues in
situ [62]. Measurement of electrical conductivity of the human brain in vivo was done
by using focal electrical current injection through intracerebral electrodes [63].
Electrical properties are important to understand because they determine the electrical current pathways in the body. This knowledge is required to make advancements
in research in domains such as Transcranial Electric Stimulation (TES) [64], Transcranial Magnetic Stimulation (TMS) [65], Electromagnetic Source Imaging (ESI) or
Electromagnetic brain mapping [66], Tumor Treating Fields (TTF) [67] and electrophysiological monitoring techniques like Electro Encephalography (EEG) [63].
TES is done by delivering weak electrical currents (1̃-2mA) directly to the scalp
for a period of 5̃-30 minutes, wherein the generated electric ﬁeld modulates neuronal
activity [64]. Fig 4.1 shows TES and TTF electrodes and headgear [68] [69]. Understanding the mechanism behind direct current delivery to the brain and how much
current is delivered allows development of three-dimensional models of the head to
validate novel electrical therapies.

4.1.1

Electrical characteristics of tumors

It is well-known that healthy and diseased tissue have diﬀerent electrical properties. Several computer models have been developed to study electric ﬁeld distribution
in tumor and normal tissues. These models show that the ratio of healthy to malig-
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(a) TES headgear [68]

(b) TTF electrodes [69]

Fig. 4.1. Non-invasive headgear for application on the scalp

nant tissue electric conductivity has an important inﬂuence on the outcome of the
treatment. Of all malignant brain tumors, 80% are gliomas, with GBM being the
most deadly form. To harness the potential of electrotherapies for GBM, we must
understand the dielectric properties of the brain and identify which of them could
be used as biomarkers. According to a study in 1957 by Schwan and Kay [70], the
dielectric properties of tissues are frequency dependent. A study of dog brains grey
matter (GM) and white matter (WM) showed the brain has a temperature dependent
conductivity between 0.01 and 10 GHz frequency [71]. Novel electric ﬁeld-based treatment modalities, such as Tumor Treating Fields (TTF), [72] now in clinical use for
GBM treatment and upcoming treatments like intratumoral modulation therapy [73]
call for a holistic understanding of the electrical nature of tumors and dielectric tissue
properties of the brain. Studies have shown the inﬂuence of low-intensity, intermediate frequency alternating electric ﬁelds in disrupting cancer cell proliferation, key
to controlling cancer [72]. A recent study showed the tumor ablation of spontaneous
brain tumors in canine patients using Irreversible Electroporation [74]. Electric pulse
parameters of 90 50-s pulses at 4 Hz were selected to maximize the area of tumor
destroyed and minimize the damage on surrounding healthy tissue. In a study by
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Jahnke et al., impedance spectroscopy was used as a biomarker for label-free realtime distinction between in vivo brain tumors and brain tissue [75].

4.1.2

Characterization of Electrical impedance

Here, we measure two electrical properties, the electrical impedance of ex vivo
bovine brain sample and the current delivered at applied dc voltage to discover ways to
create a more comprehensive brain phantom for electrical property studies. Electrical
impedance was measured using a LCR meter across the frequency range of 0.01 to 1
kHz. Measured electrical impedance varied from 145 and 2866 kΩ.

Sample preparation
We obtained an intact bovine brain from the Animal Science Department at Purdue University. It was preserved in a bag containing tissue homogenate and PBS
in a temperature-controlled ice box and used within 70 minutes of removal from the
animal to preserve the tissues initial state. Prior to the experiment, the specimen was
thoroughly washed with PBS to remove any residual tissue covering the brain surface
for placement of electrodes. Fig. 4.2a shows a section of the brain used to obtain a
ﬂat slice of 7 cm for measurements. A medical grade scalpel was used to expose the
grey and white matter, shown in Fig. 4.2b.

Electrode placement
Measurement position of electrodes in the white matter was chosen to ensure
homogeneous tissue composition around the tip. We assume a constant contact area
between the electrode and tissue due to insertion at the same depth using a customdeveloped setup.
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Fig. 4.2. a) Region of the brain used to obtain a ﬂat slice exposing GM
(peripheral) and White Matter (central) b) Sample preparation for
measurement of ex vivo electrical impedance and current monitoring

4.1.3

Experimental setup

Fig. 4.2b shows the experimental setup with 5 V dc applied from a standard
power supply between platinum coated electrodes (Anomet products, 0.5 mm diameter) placed 2 cm apart. A capillary embedded electrode setup made of glass capillaries
(internal diameter: 2 mm) placed within micromachined acrylic wells allowed platinum electrodes to be ﬁxed within the tissue at same depth. Fig. 4.3a shows setup
where voltage applied to the electrodes using a standard laboratory power supply,
varying in steps of 500 mV to measure the current output, using an ammeter. Experiments were conducted at room temperature (21C). Fig. 4.3b shows the setup used
for measuring the electrical impedance. The ends of the platinum electrodes placed
in the WM were connected to LCR meter (LCR-821, GW Instek) to read its electrical
impedance in the frequency range of 0.01 to 1kHz.

4.1.4

Current proﬁle

Fig. 4.4 shows the current proﬁle through the brain specimen continuously monitored when 5 V dc was applied between 2 cm distance for a period of 30 minutes.
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Fig. 4.3. Experiment setup used for (a) current output measurement
and (b) impedance measurements (WM: White matter, GM: Grey
matter)

Beyond 30 minutes there was no observable variation in current. The measured current followed a linearly increasing trend from 0.2 mA to 0.3 mA. A linear ﬁt to the
measured current (R2 =0.9467) indicates that the specimen behaves as a resistor.

Fig. 4.4. Current proﬁle measured in ex vivo brain specimen with
time, showing a good linear ﬁt (R2= 94.67%)

Fig. 4.5 shows variation of measured current with applied dc voltage between 0
and 10 V. Until an applied voltage of 5.7 V, current exhibits a linear trend after which
the behavior is non-linear. A 5th degree polynomial curve closely ﬁt to the data (R2
=0.9742). The equation of ﬁt line is y = 0.0001x5 - 0.0022x4 + 0.0134x3 - 0.0151x2
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- 0.0075x + 0.0097 where x is the applied dc voltage in volts and y is the current
in mA. We see an increase in measured output current until 7.5 V where there is a
sudden drop followed by steady decrease which may be indicate temporal changes
in the brain post-mortem due to absence of blood supply and ion exchange between
cells. To our knowledge, this is the ﬁrst study where current proﬁle was measured over
time in ex vivo brain tissue. Measured average impedance of the brain specimen using
LCR meter at 1 kHz at room temperature was 20.463kΩ, a resistive load, whereas,
in vivo values of mean tissue impedance using multi-contact intracerebral electrodes
were 1202+/-184 Ω for WM and 911+/- 199 Ω for GM [15].

Fig. 4.5. Current variation with applied dc voltage in the ex vivo brain specimen

The electrical nature of the brain is useful to explore electrical treatments for GBM
treatment. The variation of current with applied dc voltage in the brain specimen
suggests the possibility of using ex vivo measurements to predict the range of voltages
surgeons could apply to in vivo experiments. However, limitations exist, calling for
a systematic examination of electrical eﬀects under realistic brain conditions [76].
A comprehensive in vitro gel model based on ex vivo tissue measurements could
help understand brains electrical characteristics as biomarkers but in vivo methods
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are still going to be the benchmark that provide relevant results for applicability to
humans [32]. A correlation between ex vivo and in vivo studies is therefore crucial to
work towards in the future, to enable real time monitoring of electrical parameters in
clinical application of electrotherapies for GBM.

4.1.5

Discussion

We provided a rationale for conducting electrical property measurements to characterize brain tissues under applied dc voltage. This study is an attempt to understand the electrical nature of brain under dc conditions and could open several
research possibilities for development of electrotherapies in the future. Human brain
tissue dielectric properties, such as electrical impedance, electrical conductivity at dc
and electrical conductivity at ac frequencies, permittivity and ionic diﬀusion coeﬃcient are important parameters to determine the nature of neural activity that could
pave way for developing novel electrotherapies for GBM.
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5. CONCLUSION
This work presented the development of a wireless powered electrolytic ablation device
for tumor ablation via pH change comprising of a PZT, on board rectiﬁer, and platinum electrodes. The facile fabrication of the circuit for simple placement of components makes the device a low-cost alternative with advantages like minimally invasive
insertion and large ablations volumes. We investigated the proof-of-principle and feasibility of electrolytic ablation using the micro-device and characterized the pH zones
around the electrodes with time-lapse imaging. The use of energy transfer via ultrasound to power the micro-device oﬀers several advantages such as omni-directionality,
negligible tissue absorption at frequencies below 10 MHz, device miniaturization, reasonably deep penetration depth and multi-trigger functionality. However, there is a
trade-oﬀ between implant size (receiver dimensions) and penetration depth. In particular, deep-situated ultrasound receivers will greatly beneﬁt when axial ultrasound
wave intensity is in the near-ﬁeld region. Hence, it is advantageous to utilize the axial
direction of the transmitter for maximizing power transfer.
We also investigated charged drug transport via electrophoresis in brain-tissue
mimic phantom agarose gels at DC electric ﬁelds below 3 V/cm. The electric ﬁelds
and voltages used in the study fall within the human safety range [77]. We demonstrated that implantable ﬂushable electrodes mediated by electrophoresis improve the
transport distance of charged drugs and dyes into the brain in a predictable manner
by controlling the duration of electrophoresis and voltage applied. We introduced
a capillary embedded electrode setup and a novel fabrication of electrodes by rapid
prototyping laser micromachining and embedding it within PDMS to make the ﬂushable electrodes conformable with brain tissue to minimize inﬂammatory responses.
We also showed proof of nearly stable constant currents at diﬀerent ﬂow rates. We
also have demonstrated a novel method of continuous ﬂushing to eliminate gaseous
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bubbles formed by hydrolysis reactions. The local electric ﬁeld generated between
the biased electrodes drives charge transport. Periodic placement of electrodes enables the pulling of charged drugs through the brain parenchyma to aﬀect the speciﬁc
site of delivery in a controlled manner. Although the brain is non-homogeneous and
anisotropic, the experiments conducted in brain-mimic phantoms demonstrate the
feasibility of improving charged drug penetration after intraparenchymal injection. A
future challenge to implement this system is the requirement of more realistic brain
models to study the behavior of charged drug molecules under applied electric ﬁelds.
The simplicity of the electrophoretic transport can provide surgeons with another
valuable approach for delivering drugs to deep-seated tumors in the brain and other
organs. In vivo studies will be required to assess the applicability of both the microsystems presented in this dissertation for human use.
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6. FUTURE WORK
In the previous chapters, we demonstrated proof-of-principles of the wireless powered micro-ablation device for tumor ablation and ﬂuidic-ﬂushable electrodes for electrophoretic drug delivery and established a method of diﬀerentiating tissue properties
based on electrical impedance.

6.1

Implantable devices for the brain
Development of devices that constantly record parameters of the brain, such as the

calories burnt, changes in blood ﬂow or Electroencephalograms (EEG) and transmit
them wirelessly to receiver modules and smart phones could become commonplace
in the future. Several implantable devices for the brain, shown in Table 6.1, have
already been developed in the recent past for applications such as blood-brain barrier
opening [78], ﬂuorescence imaging of deep brain tissue [79], drug delivery and longterm observation of neuronal structures [80], study tissue penetration mechanics [81],
record extracellular pH [82] and long term neural recording [83].

6.2

Preparation of realistic tissue phantoms
Simple, robust yet inexpensive models or surrogates of human tissue for in vitro

exploratory studies of electrophoretic drug delivery and pH ablation treatment characterization are important to develop novel therapies that are administered in vivo.
Although agarose possesses several characteristics that are similar to the brain, it
does not replicate the inhomogeneity of features and anisotropy in diﬀerent directions. 0.6% w/v agarose gel used in CED studies showed a ratio of distribution
volume to infusion volume of 10, while it is 7.1 for brain [84]. This model is optimal
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Table 6.1.
Implantable devices for various brain property measurements
Device
Implanted Ultrasound

Size
12mm diameter

device

Purpose
Blood-Brain-Barrier
opening
Fluorescence imaging

Image Sensor Chip

1500 x 450 micron

for surface and
deep brain tissue

Implantable micro-optical

2.7mm diameter

ﬂuidic device

450 micron

Cylindrical Stainless

100 & 200 micron

steel probes

probe diameter

Microﬂuidic drug delivery
Study penetration
mechanics of
brain tissue
Hydrous IrOx

700 sq.micron

microelectrodes

Extracellular pH
recording

Neural probe
512.5 micron

Long term

wide PCB

neural recording

embedded in
gelatin matrix

for CED infusion studies but may not be relevant for in vivo electrophoretic transport
studies.
In electrophoresis studies, it is important to mimic the features of brain as closely
as possibly to provide the resistance to transport present in actual brain. Movement
of charged substances is aﬀected by the features of the medium. The large surface area
to volume ratio in the cerebral cortex of brain leads to convoluted features such as gyri
and sulci. Replicating these features in agarose is challenging but necessary. To create
gyri and sulci patterns, hemispherical PDMS gel coated with a hexane-absorbent
PDMS layer (bi-layer elastomer) was used [85]. Creating surrogate models combining
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materials like PDMS and agarose would allow using the mechanical elasticity of PDMS
and the ﬂexible manipulation of electrical properties of agarose.

6.3

Bubble elimination characterization

Fig. 6.1. Bubble generation at electrode area of micro-ablator

A future study involving treatment of multi-mm sized tumor nodules with the
ultrasound powered micro-ablator device and a follow up in vivo study with small
animals is planned. Before the wireless device may be used, we plan to improve its
performance for continuous treatment by characterization inside a three dimensional
phantom gel to simulate real tumor mass. We have plans to eliminate gas bubbles
formed from electrolysis a) by agitating the tip of Platinum by means of mechanical
vibration and b) by limiting treatment duration in fractions. We plan to use the
cleanroom to fabricate a micro-ablator device with Platinum electrode having precise active area and characterize exactly, the pH ablation zone in vitro with three
dimensional cell cultures and in vivo. We also plan to characterize the change in pH
from rate of generation of H+, OH- and other reactive oxygen species with magnetic
resonance imaging, a technique used by Rubinsky et al to monitor electrolysis [43].
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6.4

Staggered electrode drug delivery system for GBM
Improvements in the treatment of GBM tumors are urgently needed and such tu-

mors could beneﬁt from a reliable and eﬀective CNS drug delivery system. In order to
be clinically eﬀective, such systems should be able to deliver charged chemotherapeutic agents in clinically useful concentration to multi-cm scale target locations within
the brain in a controlled and accurate manner. This must be done without damage to
surrounding brain. Using ﬂuidic-ﬂushable electrodes, this dissertation demonstrated
a novel way of drug delivery while maintaining stable currents. It is commonly assumed that direct electric current would cause lesion and damage to neurons and glial
cells. With properly designed electrodes for delivery of safe, acceptable levels of current by using multiple staggered electrodes, one can move charged drugs in the brain
parenchyma or any other tissue where enhanced local drug concentration is desired,
without causing damage to adjacent cells.
It is now possible to use electric ﬁeld to move charged drugs (electrophoresis) and
also bring about pH changes around the electrode in the form of electrolytic ablation.
To increase the eﬃcacy of the drug delivered and provide an enhanced treatment
eﬀect, it would be necessary to use therapeutic substances that are activated at a
certain pH. Since the value of pH may be controlled by the duration of ablation
treatment, quantifying pH change is necessary to further develop the technique of in
vivo electrophoresis. Also, since the charge of a drug is crucial for the distance it
is transported to, highly charged drugs need less time to be delivered. Therefore in
the future, identifying methods to obtain greater surface charge through chemical or
physical modiﬁcation may be explored.
Staggered electrodes, i.e. electrodes placed at periodic distances to pull charges
with electrophoresis is practical in clinical setups. This is useful to achieve a consistent
and uniform volume distribution of drugs. The schematic in Fig. 6.2 illustrates a
cross-sectional view of such a staggered electrode system consisting of a) three electroﬂuidic electrodes interfacing with percutaneous port-catheter system with buﬀer inlet
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and outlet for ﬂushing the electrolysis byproducts b) a drug injection port (could
be an Ommaya reservoir implanted sub-cutaneously). Various conﬁgurations of the
staggered electrodes could be developed to customized resected cavity geometries via
MRI image analysis.
The schematic is a vision of a clinically-acceptable implantable system that incorporates all components for electrical and ﬂuidic connections needed for in vivo brain
electrophoresis, including injection and sampling ports, injection micro-catheters, and
intracerebral drive electrodes. Using a combination of laser-micromachining and polymer micro molding, the injection port, electro-ﬂuidic electrodes, and percutaneous
connectors could be fabricated in a straightforward manner. Electrodes could be
sealed in molded PDMS (silicone), which has shown good mechanical and sealing
properties in our in vitro experiments in agarose gel brain tissue mimic phantoms.
In the case of leakage, we could use other polymers such as PMMA that oﬀer a more
robust bond between the two PDMS cover halves. We have another option to use
oﬀ-the-shelf Tygon or polyimide tubing/catheter for the capillary approach to resolve any leakage problems. Another alternative is to use custom-made multi-lumen
micro-catheters.

6.5

Integration with communication module
Wireless powered deep-seated implants could greatly beneﬁt from wireless com-

munication to the external world. This requires a dedicated communication module
that detects the state of the tumor after treatment and send data about the state to
a receiving station outside the body (could be a smart phone device or a computer).
Future work could be done on determining the ideal power requirements for various
sizes of micro-ablator prototypes, further miniaturizing the implants to seed-sized
implants and developing communication and remote-control protocols for network of
implants embedded within a solid tumor. A review of common powering mechanisms

Fig. 6.2. Schematic of a staggered electrode implantable in vivo brain electrophoresis system
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for wireless communication include ultrasound powering [86], galvanic coupling [87],
ionic and volume conduction [88] and vibration-based methods [89].
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